Linked research, clinical, and regulatory source pathways.
Company profile
About Infervision
Infervision Medical Technology Co., Ltd. (推想医疗科技股份有限公司) was established in 2016 with the vision of "improving life and health through AI." The company has positioned itself as an international leader in hospital-wide AI solutions. Infervision employs a comprehensive "horizontal and vertical" strategic approach combined with international expansion. Horizontally, the company covers multiple disease areas including cancer, infectious diseases, cardiovascular disease, cerebrovascular disease, and trauma. Vertically, it follows the patient care pathway from disease screening and diagnosis through intervention and treatment to patient health management and medical research. The company provides advanced integrated smart healthcare services to governments, medical institutions, physicians, and patients. Infervision's products utilize deep learning technology and convolutional neural network models that mimic human cognitive processes. The company's solutions have obtained regulatory clearances from China's NMPA, US FDA, EU CE, UK UKCA, and Japan's PMDA, representing access to five major global markets. Products are deployed in over 1,000 healthcare institutions across more than 30 countries worldwide. The company has accumulated over 390 patents (granted and pending), published more than 350 SCI core papers, and maintains a strong research collaboration network with leading academic medical centers.
Company description Infervision official website
Claim this profile to manage Company information and connect with the Health AI Central audience.
01 · Operating footprint
Where the Company operates
Company-profile context for clinical focus, customers, deployment, integration, milestones, and partnerships.
Clinical focus
- Aortic dissection
- Bone fractures
- Cerebral hemorrhage
- Coronary artery disease
- COVID-19
- Intracranial aneurysm
- Liver disease
- Lung cancer
- Pneumonia
- Pulmonary nodules
- Stroke
- Tuberculosis
- Urological conditions
Who it serves
- Government Health Agencies
- Health Systems
- Hospitals
- Radiology Departments
- Research Institutions
Deployment & integration
Deployment information is currently being developed.
Recorded integration context: EHR systems, HIS, PACS.
Geographic context
Company milestones
Platform expansion
WHO recommendation for InferRead DR Chest tuberculosis screening (2025); CE MDR and UKCA certification for surgical planning AI (2025); NMPA approval for bone fracture X-ray triage software (2025); Nature Communications publication on AI 3D reconstruction (2025); npj Digital Medicine publication on virtual thin-slice CT (2025)
Partnerships
Recorded partners
- Beijing University People's Hospital
- China-Japan Friendship Hospital
- Jiangsu Provincial People's Hospital
- Northeastern University
- PLA General Hospital (301 Hospital)
- Shandong Provincial Hospital
- Shanghai Pulmonary Hospital
- Stop TB Partnership
- UCLA
- WHO
- Xiangya Second Hospital of Central South University
02 · Flagship portfolio
Products, workflows, and platform capabilities
Selected source-backed Company products and the available commercial context.
No source-backed Company products are currently listed.
03 · Research intelligence
Research Intelligence evidence
Publications, preprints, clinical validation, and regulatory records in Evidence Position order.
Evidence position
Publications, clinical validation, and regulatory records connected to this Company appear here.
Research
Publications & preprints
Short-term quantitative CT trajectories of pulmonary Ground-Glass nodules during immune checkpoint inhibitor Therapy: A matched surveillance cohort study.European journal of radiology · Jul 10, 2026
Predictive value of delta-radiomic features for the prognosis of patients with stage IA lung adenocarcinoma.Clinical imaging · Jun 1, 2026
3D deep learning model to predict the recurrence of stage IA invasive lung adenocarcinoma after sub-lobar resection: a multicenter retrospective cohort study.Journal of imaging informatics in medicine · Mar 31, 2026
TabPFN-driven ternary classification of stage IA lung adenocarcinoma subtypes using AI-derived histogram features a retrospective multicenter cohort study.International journal of surgery (London, England) · Feb 3, 2026
Corrigendum to "Dual-energy CT radiomics for predicting neoadjuvant chemotherapy response in locally advanced gastric cancer: A dual-vendor validation study" [Eur. J. Surg. Oncol. 51 (2025) 110548].European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology · Feb 1, 2026
Improvement of machine learning models for predicting high-grade subtypes of lung adenocarcinoma based on delta radiomics: A multicenter cohort study.European journal of radiology open · Dec 1, 2025
Clinical validation
Clinical-trial records
Fibrotic Interstitial Lung Disease Early Recognition and Strategic Therapy Study in ChinaNCT06655090 · Sponsor · RECRUITING
Performance Study for InferRead CT Pneumonia.AINCT04955704 · Sponsor · UNKNOWN
Clinical Validation of InferRead Lung CT.AINCT04119960 · Sponsor · COMPLETED
Regulatory
Regulatory records
InferRead Lung CT.AIK240554 · 510k · May 16, 2025
InferRead CT Stroke.AIK211179 · 510k · Aug 12, 2021
04 · Company-reported outcomes
Outcomes and case studies
Company-reported outcomes and customer stories are distinct from linked Research Intelligence evidence.
CTA coronary artery reconstruction and post-processing
Cerebral hemorrhage AI automated reconstruction and post-processing
Detection of small pulmonary nodules and hidden lesions
Longitudinal comparison of imaging changes for treatment efficacy assessment
05 · Leadership
Leadership team
Leadership profiles and professional links from the current Company record.
No active leadership profiles are currently listed.
06 · Company updates
Updates from Infervision
Recent articles published on Infervision's official website.
No Company updates are currently listed.
07 · HAIC coverage
Coverage and analysis
Health AI Central reporting that mentions this Company.
No HAIC coverage is currently linked to this Company.
08 · Official presence
Company sources and channels
Curated official destinations from the active Company record.
09 · Market pathway
Additional Companies in this Market
Other active Companies in the same market, selected alphabetically from the HAIC directory.
Market context
Medical Imaging & Radiology
Companies that apply AI to analyze medical images for diagnostic purposes, workflow optimization, or clinical decision support. Covers general radiology (X-rays, CT scans, MRIs, ultrasounds) across multiple organ systems, as well as specialized imaging in ophthalmology and dermatology.
Explore the full market directory or compare this Company with additional active profiles.
View all Companies in this market10 · Pro research
Coming soon
Expanded Company research is in development.
Health AI Central Pro · Coming Soon
Deeper Company research is coming soon.
Pro Research will introduce expanded technical context, linked evidence analysis, and comparative Company research.
Expanded product, deployment, integration, and partnership research.
Record-level provenance and review context.